Literature DB >> 14633686

High-resolution deletion mapping of 15q13.2-q21.1 in transitional cell carcinoma of the bladder.

Rachael Natrajan1, Jari Louhelainen, Sarah Williams, Jonathan Laye, Margaret A Knowles.   

Abstract

Deletions found in several types of human tumor, including carcinomas of the colorectum, breast, and lung, suggest the presence of a potential tumor suppressor gene(s) on chromosome 15. Common regions of deletion in these tumors are at 15q15 and 15q21. Here, we have analyzed loss of heterozygosity (LOH) on chromosome 15 to ascertain its potential involvement in the development and progression of transitional cell carcinoma (TCC) of the bladder. A panel of 26 polymorphic markers, spanning 15q12-15q22, were used to map regions of LOH in 51 TCCs. LOH was found for at least one marker in the region 15q14-15q15.3 in 20 of 51 (39%) tumors. Deletion mapping defined two minimum regions of deletion: a distal region between the markers D15S514 and D15S537 at 15q15.1-15q15.3 (estimated as 3 Mb) and a more proximal region between the markers D15S971 and D15S1042 at 15q14 (estimated as 1.1 Mb). Analysis of a panel of 33 bladder tumor cell lines revealed regions of contiguous homozygosity for markers in 15q15, indicating likely LOH. Fluorescence in situ hybridization analysis demonstrated that mitotic recombination is the predicted mechanism of LOH in two of these. These regions of LOH on 15q may contain tumor suppressor genes the loss or inactivation of which is associated with TCC development. The DNA repair gene RAD51 at 15q15.1 represents a candidate 15q tumor suppressor gene. Expression analysis of rad51 protein in tumor cell lines revealed variable levels of expression but no significant loss of expression in cell lines with likely 15q LOH.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14633686

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors.

Authors:  Raisa Vuononvirta; Neil J Sebire; Anthony R Dallosso; Jorge S Reis-Filho; Richard D Williams; Alan Mackay; Kerry Fenwick; Anita Grigoriadis; Alan Ashworth; Kathy Pritchard-Jones; Keith W Brown; Gordan M Vujanic; Chris Jones
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

2.  Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy.

Authors:  Chien-Chung Chang; Michael Campoli; Nicholas P Restifo; Xinhui Wang; Soldano Ferrone
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

3.  Single nucleotide polymorphism profiling assay to confirm the identity of human tissues.

Authors:  Ronald Huijsmans; Jan Damen; Hans van der Linden; Mirjam Hermans
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

4.  Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors.

Authors:  Isabel Maleno; Natalia Aptsiauri; Teresa Cabrera; Aurelia Gallego; Annette Paschen; Miguel Angel López-Nevot; Federico Garrido
Journal:  Immunogenetics       Date:  2010-11-18       Impact factor: 2.846

5.  Large-scale evaluation of candidate genes identifies associations between DNA repair and genomic maintenance and development of benzene hematotoxicity.

Authors:  Qing Lan; Luoping Zhang; Min Shen; William J Jo; Roel Vermeulen; Guilan Li; Christopher Vulpe; Sophia Lim; Xuefeng Ren; Stephen M Rappaport; Sonja I Berndt; Meredith Yeager; Jeff Yuenger; Richard B Hayes; Martha Linet; Songnian Yin; Stephen Chanock; Martyn T Smith; Nathaniel Rothman
Journal:  Carcinogenesis       Date:  2008-10-31       Impact factor: 4.944

6.  Putative tumour suppressor gene necdin is hypermethylated and mutated in human cancer.

Authors:  L E De Faveri; C D Hurst; F M Platt; C F Taylor; J-A Roulson; M Sanchez-Carbayo; M A Knowles; E J Chapman
Journal:  Br J Cancer       Date:  2013-04-02       Impact factor: 7.640

7.  miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.

Authors:  Bairong Xia; Shanshan Yang; Tianbo Liu; Ge Lou
Journal:  Mol Cancer       Date:  2015-03-11       Impact factor: 27.401

8.  Genetic instability in the RAD51 and BRCA1 regions in breast cancer.

Authors:  Maria Nowacka-Zawisza; Magdalena Bryś; Hanna Romanowicz-Makowska; Andrzej Kulig; Wanda M Krajewska
Journal:  Cell Mol Biol Lett       Date:  2006-12-18       Impact factor: 5.787

9.  Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis.

Authors:  Tania Rossi; Davide Angeli; Michela Tebaldi; Pietro Fici; Elisabetta Rossi; Andrea Rocca; Michela Palleschi; Roberta Maltoni; Giovanni Martinelli; Francesco Fabbri; Giulia Gallerani
Journal:  Cancers (Basel)       Date:  2022-08-14       Impact factor: 6.575

10.  Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study.

Authors:  Karin Broberg; Elizabeth Huynh; Karin Schläwicke Engström; Jonas Björk; Maria Albin; Christian Ingvar; Håkan Olsson; Mattias Höglund
Journal:  BMC Cancer       Date:  2009-05-11       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.